| Project/Area Number |
21650108
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Shizuoka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKAHARA Harumi 浜松医科大学, 医学部, 教授 (10187031)
TAKEHARA Yasuo 浜松医科大学, 医学部附属病院, 准教授 (70188217)
NAKAMURA Satoki 浜松医科大学, 医学部附属病院, 助教 (20377740)
OKANO Takashi 東京慈恵会医科大学, 医学部, 教授 (90194373)
FUJIE Michio 浜松医科大学, 技術部, 技術専門員 (90397373)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MULLER Robert (MULLER NICOLAS Henry) University of Mons, Belgium, School of Medicine and Pharmacy, 教授(学部長)
F. DAVID Wiemer University of Iowa, USA, Department of Medicine, 教授(学部長)
GYORGY Keglevich Budapest University of Technology and Economics, Hungary, Dept. of Organic Chemistry and Technology, 教授(学部長)
C. SURESH Reddy Sri Venkateswara University, India, Dept. of Chemistry, 准教授
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2009: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | がん早期発見 / がん早期治療 / MRI造影剤 / リン糖抗がん剤 / 複合機能化 |
|---|
| Research Abstract |
The project contained three sub-research thema(1).(3) and the progress of the research was 80% completion.(1) R & D of sugar dendritic Gd-DTAP complex for MRI contrast agents DEN-OH and the modification was 80% successful to develop novel blood pool MRI contrast agents and DEN-OH(prepared via hydrolysis route) drew clear blood vessels and liver cancers. The r1 value for DEN-OH and modified sugar Dendritic Gd-DTPA complexes were 20. 31[mmol-1・s-1], which are superior to clinically used Gd-DTPA(r1=3. 5[mmol-1・s-1]) by 10 times.(2) Phospha sugar antitumor agents were developed. Among them, TBMPP and DBMPP were most active and the analogs showed 10-1000 times more active than Gleevec(clinically used drug). TBMPP suppressed the expression of Cdc25B, which is a common factor of cell cycle for various kinds of cancer cells. Therefore, phospha sugars must most probably be developed as new"Multiple Type Molecular Targeted Antitumor Agents"and the drug may cure various types of cancer patients by the single drug.(3) The application of the results(1) and(2) provided new drugs for diagnosing and curing cancers in the sub-research thema, whose results will not be disclosed at the present stage.
|
